STOCK TITAN

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.

The presentation and question and answer session will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event. A copy of the presentation slides will be also posted on the company’s website beginning on Monday, January 10, 2022, at 8:00 a.m. ET.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com 
617.599.8178


Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Stock Data

5.10B
81.04M
13.24%
95.98%
8.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.